KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $194.9 million.

  • Vertex Pharmaceuticals' Share-based Compensation rose 557.96% to $194.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $696.1 million, marking a year-over-year decrease of 584.34%. This contributed to the annual value of $698.5 million for FY2024, which is 2018.24% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Share-based Compensation of $194.9 million as of Q3 2025, which was up 557.96% from $167.3 million recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Share-based Compensation registered a high of $208.6 million during Q4 2023, and its lowest value of $103.0 million during Q3 2021.
  • Its 5-year average for Share-based Compensation is $144.2 million, with a median of $130.9 million in 2023.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 8708.52% in 2023, then tumbled by 1955.9% in 2024.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Share-based Compensation stood at $118.6 million in 2021, then fell by 5.99% to $111.5 million in 2022, then skyrocketed by 87.09% to $208.6 million in 2023, then decreased by 19.56% to $167.8 million in 2024, then grew by 16.15% to $194.9 million in 2025.
  • Its Share-based Compensation stands at $194.9 million for Q3 2025, versus $167.3 million for Q2 2025 and $166.1 million for Q1 2025.